Silexion Therapeutics LTD (SLXN)
Silexion Therapeutics LTD Statistics
Share Statistics
Silexion Therapeutics LTD has 8.69M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 8.69M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 4,908 |
| FTD / Avg. Volume | 0.1% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 0.99 and the forward PE ratio is -0.6. Silexion Therapeutics LTD's PEG ratio is 0.
| PE Ratio | 0.99 |
| Forward PE | -0.6 |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | -8192.41 |
| P/FCF Ratio | -1.95 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Silexion Therapeutics LTD.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.64, with a Debt / Equity ratio of -263.
| Current Ratio | 0.64 |
| Quick Ratio | 0.64 |
| Debt / Equity | -263 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.06 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $1,500,818.18 |
| Employee Count | 11 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.06, so Silexion Therapeutics LTD's price volatility has been higher than the market average.
| Beta | 0.06 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 1.03 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 53.39 |
| Average Volume (20 Days) | 5,008,077 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | n/a |
| Net Income | 16.51M |
| EBITDA | n/a |
| EBIT | n/a |
| Earnings Per Share (EPS) | 2.03 |
Balance Sheet
| Cash & Cash Equivalents | n/a |
| Total Debt | 526K |
| Net Cash | n/a |
| Retained Earnings | -43.25M |
| Total Assets | 2.86M |
| Working Capital | -1.27M |
Cash Flow
In the last 12 months, operating cash flow was -8.4M and capital expenditures -22K, giving a free cash flow of -8.42M.
| Operating Cash Flow | -8.4M |
| Capital Expenditures | -22K |
| Free Cash Flow | -8.42M |
| FCF Per Share | -1.03 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SLXN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for SLXN is $5, which is 400% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 400% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Nov 29, 2024. It was a backward split with a ratio of 1:9.
| Last Split Date | Nov 29, 2024 |
| Split Type | backward |
| Split Ratio | 1:9 |
Scores
| Altman Z-Score | -40.13 |
| Piotroski F-Score | 1 |